<DOC>
	<DOCNO>NCT02434393</DOCNO>
	<brief_summary>The purpose research study characterize mechanism contribute cognitive impairment accelerate cognitive decline Late Life Depression ( LLD ) . This non-randomized , observational , non-treatment study . One hundred twenty ( 120 ) subject meet criterion Major Depression LLD enrol period 30 month . Data additional 300 non-depressed subject use ADNI study comparison . Depression history , symptom severity health information collect initial psychiatric visit determine eligibility . A 3 Tesla ( 3T ) Magnetic resonance imaging ( MRI ) scan florbetapir ( 18F-AV-45 ) amyloid image conduct ADNI clinic site visit . Collection plasma serum biomarkers , clinical assessment cognitive assessment conduct two time point . Blood sample also collect genetic analysis .</brief_summary>
	<brief_title>Characterizing Cognitive Decline Late Life Depression : The ADNI Depression Project</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Current DSMIV diagnosis Major Depressive Disorder , unipolar type , without psychotic feature six week minimum duration current depressive episode . 2 . English Speaking 3 . 65+ year age 4 . Hamilton Depression Rating Scale score ≥ 15 5 . Able give inform consent 6 . Willing undergo one MRI ( 3 Tesla ) one PET scan ( Amyloid image ) 7 . Able fit MRI machine comfortably ( BMI ≤ 38 ) 8 . Agrees collection blood GWAS , apolipoprotein E ( APOE ) test DNA RNA test 9 . Agrees collection blood biomarker test 10 . Agrees collection additional blood sample tobedetermined assay telomere length measurement 11 . Visual auditory acuity adequate neuropsychological test 12 . Completed six grade education establish work history ( sufficient exclude mental retardation ) 13 . Study partner available frequent contact subject ( e.g . average 10 hour per week ) , accompany subject clinical visit duration protocol . 1 . Current diagnosis axis 1 psychiatric disorder ( exception Simple Phobias Generalized Anxiety Disorder ) 2 . Evidence Dementia ( MMSE &lt; 25 ) 3 . Any electroconvulsive therapy within past 6 month 4 . Undergoing antidepressant psychotherapy treatment ( exception list 4.3 . Treatment Exclusion Exceptions ) 5 . Any significant neurological disease ( i.e . Parkinson 's disease , epilepsy , cortical stroke , traumatic brain injury ) 6 . History alcohol substance abuse dependence within past 2 year ( DSMIV criterion ) 7 . Any active serious suicidal ideation , include ideation , plan intent carry plan , assess Hamilton Depression Rating Scale ( HDRS ) 8 . Any significant systemic illness unstable medical condition could lead difficulty comply protocol 9 . History surgical procedure effect study outcomes 10 . Residence skilled nursing facility 11 . Participation clinical study involve neuropsychological measure use ADNID may impact study outcomes 12 . Investigational agent prohibit one month prior entry duration trial 13 . Exclusion amyloid image florbetapir : Current recent participation procedure involve radioactive agent total radiation dose exposure subject give year would exceed limit annual total dose commitment set forth US Code Federal Regulations ( CFR ) Title 21 Section 361.1 14 . Known history MRI scan evidence infection , infarction , focal lesion . Subjects multiple lacunes lacunes critical memory structure exclude 15 . Presence pacemaker , aneurysm clip , artificial heart valve , ear implant , metal fragment foreign object eye , skin body , claustrophobia 16 . Pregnant , lactating , childbearing potential ( i.e . woman must two year postmenopausal surgically sterile )</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Depression</keyword>
	<keyword>Late Life Depression</keyword>
	<keyword>LLD</keyword>
	<keyword>amyloid imaging</keyword>
	<keyword>biomarkers</keyword>
</DOC>